Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on April 4, 2025
Medical Filtration Market worth $9.35 billion by 2030, at a 6.8%, says MarketsandMarkets™
GlobeNewswire
·
April 4, 2025
Delray Beach, FL, April 04, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Medical Filtration Market Is projected to reach USD 9.35 billion by 2030 at a CAGR of 6.8%, as per the recent study by MarketsandMarkets™. The combination of regulatory frameworks, …
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
GlobeNewswire
·
April 4, 2025
TORONTO and HAIFA, Israel, April 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, Germany: J90) (“NurExone” or the “Company”) is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non- …
Better Choice Company Signs Definitive Agreement for SRx Health Solutions to Convert CAD$4 Million in Debt to Equity
GlobeNewswire
·
April 4, 2025
TAMPA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, is pleased to announce that SRx Health Solutions, Inc. (“SRx Health”) has signed a …
Dental Equipment Market worth US$9.3 Billion by 2029 driven by Specialized Dental Equipment | MarketsandMarkets™.
GlobeNewswire
·
April 4, 2025
Delray Beach, FL, April 04, 2025 (GLOBE NEWSWIRE) -- The global dental equipment market , valued at US$6.5 billion in 2023, is forecasted to grow at a robust CAGR of 6.2%, reaching US$6.9 billion in 2024 and an impressive US$9.3 billion by 2029. The dental …
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
GlobeNewswire
·
April 4, 2025
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination with atezolizumab in patients with platinum-resistant …
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
GlobeNewswire
·
April 4, 2025
Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meeting Long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures (FOS) Exploratory analysis of efficacy of …
NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock
GlobeNewswire
·
April 4, 2025
EDEN PRAIRIE, Minn., April 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological …
Entourage Health Corp. Announces Closing of Plan of Arrangement
GlobeNewswire
·
April 4, 2025
TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE) (the “Company” or “Entourage”) is pleased to announce the closing of the previously announced plan of arrangement (the “Arrangement”) pursuant to …
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease
GlobeNewswire
·
April 4, 2025
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory …
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
GlobeNewswire
·
April 4, 2025
PALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today …
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 4, 2025
DALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of …
EluPro™ Named as 2025 Edison Award Winner
GlobeNewswire
·
April 4, 2025
Innovative Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Pacemakers and Neurostimulators Earns Bronze in Post-Surgical Recovery Solutions Category SILVER SPRING, Md., April 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia …
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 4, 2025
WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare …
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
GlobeNewswire
·
April 4, 2025
MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company’s existing common stock repurchase program, bringing the aggregate capacity of …
Best Cutting and Bulking Steroids - Buy Oral Steroid Stacks for Muscle Gain, Fat Loss and Strength from CrazyBulk
GlobeNewswire
·
April 4, 2025
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Using steroids for bodybuilding is typically divided into two distinct phases: the bulking phase and the cutting phase. Each phase has specific goals—bulking focuses on gaining muscle mass and strength, while …
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 4, 2025
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on …
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
GlobeNewswire
·
April 4, 2025
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers – – Findings support continued …
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 4, 2025
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees restricted stock units (RSUs) …
AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States
GlobeNewswire
·
April 4, 2025
LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces plans to launch its microRNA Signature …
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 4, 2025
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it …